LY3372689   Click here for help

GtoPdb Ligand ID: 11953

Synonyms: LY-3372689
Compound class: Synthetic organic
Comment: LY3372689 is a O-GlcNAcase (OGA) inhibitor that was developed by Eli Lilly as a Tau modulator for Alzheimer's disease. Its structure was revealed during the 'first disclosure' session at the ACS Spring 2022 meeting, and it is the chemical structure that is claimed in Eli Lilly's patent WO2018140299A1 [1]. Information from clinical trial records indicates that LY3372689 is administered orally.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 121.62
Molecular weight 383.14
XLogP 0.66
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=O)Nc1nc(c(s1)CN1CC[C@@H](C[C@@H]1C)OCc1noc(n1)C)F
Isomeric SMILES C[C@H]1C[C@H](CCN1Cc1c(F)nc(NC(=O)C)s1)OCc1noc(C)n1
InChI InChI=1S/C16H22FN5O3S/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12H,4-8H2,1-3H3,(H,18,20,23)/t9-,12-/m0/s1
InChI Key FRVXHWNHGWUTQO-CABZTGNLSA-N
References
1. Dreyfus NJF, Lindsay-Scott PJ. (2018)
N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor.
Patent number: WO2018140299A1. Assignee: Eli Lilly And Company. Priority date: 27/01/2017. Publication date: 02/08/2018.